Core Insights - Clearmind Medicine Inc. has successfully completed patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] - The first cohort showed promising safety and efficacy results, indicating a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms [2][4] - The rapid enrollment of the second cohort underscores the commitment of collaborating clinical centers to advance innovative treatments for AUD, a condition with limited effective options affecting millions globally [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [6] Clinical Trial Details - The multinational Phase I/IIa trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with dosing for the second cohort expected to start soon [4]

Core Viewpoint - Clearmind Medicine Inc. is implementing a reverse stock split to comply with Nasdaq regulations, which will significantly reduce its outstanding shares while maintaining authorized share capital [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will occur at a ratio of 40 for 1 on December 15, 2025, reducing outstanding shares from approximately 60 million to 1.5 million [1][2]. - The board of directors approved this decision on November 12, 2025, and no fractional shares will be issued; instead, they will be rounded up to the nearest whole share [2]. Group 2: Stock Performance - Following the announcement, CMND's share price dropped 29.92% in after-hours trading, with the stock closing at $0.11 before the announcement, reflecting a decrease of 6.08% [3]. - The current stock price is $2.61, indicating a decrease of approximately 12.14% [3]. - The stock has shown significant volatility, trading between $2.54 and $3.25 on the day of the announcement, with a yearly high of $87.20 and a low of $2.54 [4]. Group 3: Market Capitalization and Trading Volume - CMND's market capitalization is approximately $14.27 million, with a trading volume of 247,625 shares [4].

Core Insights - Clearmind Medicine Inc. has published a review article validating the therapeutic potential of its candidate MEAI in treating alcohol use disorder (AUD) [1][2] - The review highlights MEAI's advantages over classical psychedelics, including a milder subjective experience and lower abuse potential [2] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, particularly AUD [4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents [5] Therapeutic Effects of MEAI - Recreational users typically take MEAI in doses of 1 to 2 mg/kg, reporting positive effects such as reduced desire to consume alcohol within 4 hours [6] - MEAI's receptor interaction profile suggests it may stimulate serotonin release while having a lower risk of abuse compared to other substances like MDMA [6] Adverse Effects - Users of MEAI have not reported serious adverse events, and it is expected to have milder toxicity compared to MDMA due to its receptor interactions [6]

Core Points - Clearmind Medicine Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000, as confirmed by a notification letter from Nasdaq on December 10, 2025 [1][2] - The company is under continued monitoring by Nasdaq for compliance with the Minimum Stockholders' Equity Rule, with potential delisting if compliance is not demonstrated in the next periodic report [2] - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [3] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [4]

Core Viewpoint - Clearmind Medicine Inc. is implementing a 1-for-40 reverse stock split to comply with Nasdaq's minimum bid price requirement, following a significant decline in its stock price and market capitalization [2][4]. Group 1: Stock Performance - Clearmind Medicine shares fell 29.92% in after-hours trading, closing at $0.0801, down 6.08% on the day [1]. - The stock has experienced a 91.41% decline over the past year, with a market capitalization of $6.86 million [5]. Group 2: Reverse Stock Split Details - The reverse stock split will reduce the outstanding common shares from 59.99 million to 1.50 million, effective December 15 [3]. - The company's authorized share capital will remain unchanged, and no fractional shares will be issued, with all fractions rounded up to the nearest whole share [3]. Group 3: Board Approval and Adjustments - The board of directors approved the reverse split on November 12, in accordance with the company's articles of association [4]. - A proportionate adjustment will be made to the per-share exercise price and the number of shares issuable upon exercise of all outstanding options and warrants [4].

Core Viewpoint - Clearmind Medicine Inc. will conduct a reverse share split at a ratio of 1-for-40 to regain compliance with the Nasdaq Minimum Bid Price Rule, effective December 15, 2025 [1][2]. Group 1: Reverse Share Split Details - The reverse share split was approved by the Company's board of directors on November 12, 2025 [2]. - Following the reverse split, the number of issued and outstanding Common Shares will decrease from 59,991,852 to 1,499,796 [3]. - No fractional Common Shares will be issued; all fractional shares will be rounded up to the nearest whole share [4]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder [5]. - The Company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5].

Core Viewpoint - Clearmind Medicine Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its closing bid price has been below $1.00 for the last 30 consecutive business days [1][2]. Compliance Period - The company has been granted a 180-calendar day compliance period until June 2, 2026, to regain compliance with the minimum bid price requirement [2]. - During this compliance period, the company's shares will continue to be listed and traded on Nasdaq under the symbol "CMND" [2]. Regaining Compliance - To regain compliance, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days during the compliance period [2]. - If compliance is not achieved by June 2, 2026, the company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements [3]. Monitoring and Future Actions - The company intends to monitor its closing bid price and will consider options to resolve the non-compliance issue as necessary [4]. - There is no assurance that the company will regain compliance with the minimum bid price requirement or other Nasdaq listing criteria [4]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including alcohol use disorder [5]. - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [5].

As filed with the Securities and Exchange Commission on December 5, 2025. Registration No. 333-291817 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) | British Columbia | 2834 | Not Applicable | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organiz ...

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has announced significant progress in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The company reported positive top-line results from the first cohort of six participants, dosed at prestigious institutions including Johns Hopkins University and Yale University [4] - The independent Data and Safety Monitoring Board (DSMB) unanimously approved the continuation of the clinical trial after an interim safety review [5] - Enrollment has commenced at a new clinical site in Israel, Tel Aviv Sourasky Medical Center, enhancing patient recruitment efforts [6] Group 2: Market Context and Impact - AUD affects over 28 million adults in the U.S., incurring societal and economic costs exceeding $249 billion annually, highlighting the need for effective treatments [3] - Current treatment options for AUD are limited in efficacy and accessibility, positioning Clearmind's CMND-100 as a potentially transformative solution [3] Group 3: Company Overview - Clearmind is focused on developing novel neuroplastogen-derived therapeutics to address significant health issues, including AUD [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans for further acquisitions [8]